A SINGLE-ARM PHASE 2 STUDY OF DARATUMUMAB IN PREVIOUSLY TREATED STK11/LKB1 MUTATED NON-SMALL CELL LUNG CANCER

Brief description of study

This is a study of a drug combination called daratumumab for patients with advanced lung cancer that has spread to other parts of the body and has a specific genetic mutation called STK11/LKB1. Patients who have already received and not responded to standard treatments can participate. This study will help see if daratumumab can help these patients, even though they have already had other treatments like chemotherapy, immunotherapy, and targeted therapy. Patients will get daratumumab by injection under the skin every week for a total of 8 times, then every 2 weeks for 8 more times, then every 4 weeks. The goal of this study is to test the effectiveness of this drug combination specifically for patients with advanced lung cancer. Patients will be checked on regularly to determine if the medicine is helping.


Clinical Study Identifier: s22-01512
Principal Investigator: Sally Lau.
Other Investigators: Joshua K Sabari, Elaine Shum, Vamsidhar Velcheti, Jessica Wang.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.